Kidney Precision Medicine Project
Recruiting now
Conditions studied: Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, Type 1 Diabetes (T1D)
In brief
Acute kidney injury (AKI) and chronic kidney disease (CKD) impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. Despite significant effort from industry and academia, development of pharmacologic therapies for AKI and CKD has been hampered by: Non-predictive animal models The inability to identify and prioritize human targets The limited availability of human kidney biopsy tissue A poor understanding of AKI and CKD heterogeneity Historically, AKI and CKD have been described as single, uniform diseases. However, growing consensus suggests that different disease pathways lead to different subgroups of AKI and CKD (AKIs and CKDs). Access to human kidney biopsy tissue is a critical first step to define disease heterogeneity and determine the precise molecular pathways that will facilitate identification of specific drug targets and ultimately enable individualized care for people with AKI and CKD. A number of research centers across the United States are collaborating to bring state-of-the-art technologies together to: * Ethically obtain and evaluate kidney biopsies from participants with AKI or CKD * Define disease subgroups * Create a kidney tissue atlas * Identify critical cells, pathways, and targets for novel therapies The KPMP is made up of three distinct, but highly interactive, activity groups: * Recruitment Sites: The recruitment sites (RS) are responsible for recruiting participants with AKI or CKD into the longitudinal study and performing the kidney biopsy. * Tissue Interrogation Sites: The tissue interrogation sites (TIS) are responsible for developing and using innovative technologies to analyze the biopsy tissue. * Central Hub: The central hub is responsible for aggregating, analyzing, and visualizing the generated data and providing scientific, infrastructure, and administrative support for the KPMP consortium.
Key facts
- Study ID
- NCT04334707
- Run by
- Icahn School of Medicine at Mount Sinai
- People needed
- 1000
- Starts
- 2019-09-01
- Expected to finish
- 2027-06-30
- Last updated by the study team
- 2026-04-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Arizona — Tucson, Arizona, United States (enrolling)
- Yale University — New Haven, Connecticut, United States (enrolling)
- University of Illinois Chicago — Chicago, Illinois, United States (enrolling)
- Johns Hopkins University — Baltimore, Maryland, United States (enrolling)
- Boston Medical Center — Boston, Massachusetts, United States (enrolling)
- Joslin Diabetes Center — Boston, Massachusetts, United States (enrolling)
- University of Minnesota — Minneapolis, Minnesota, United States (enrolling)
- Mayo Clinic, Rochester — Rochester, Minnesota, United States (enrolling)
- Mount Sinai — New York, New York, United States (enrolling)
- University of North Carolina — Chapel Hill, North Carolina, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- University of Texas at Southwestern — Dallas, Texas, United States (enrolling)
- University of Washington — Seattle, Washington, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.